Novocure Highlights Use Of Tumor Treating Fields Therapy In Treatment Of Non-Small Cell Lung Cancer At 2023 World Conference On Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Novocure (NASDAQ:NVCR) will participate in the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore. The company will present new post-hoc analysis of data from its phase 3 LUNAR trial in metastatic non-small cell lung cancer. The trial demonstrated a significant extension in overall survival for patients treated with Tumor Treating Fields (TTFields) therapy and standard systemic therapies. Novocure is also partnering with the IASLC to provide research grants for innovative research on TTFields in the treatment of non-small cell lung cancer.
September 08, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novocure's new data from the LUNAR trial showing significant survival extension for patients treated with TTFields therapy could potentially boost investor confidence and positively impact the company's stock.
The positive results from the LUNAR trial could potentially lead to increased adoption of Novocure's TTFields therapy, which would likely result in increased revenues for the company. This could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100